Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported 
Shein Scales Back Vietnam Operations as US Trade Rules Shift 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
ADNOC Gas Targets Up to $4B Profit in 2026 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
OpenAI Restricts Astra AI Over Cyberattack Risks 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
Goldman Sachs Sees US Stock Buybacks Outpacing Equity Issuance as AI Funding Rises 
Natura Q2 Profit Plunges 92% as Financial Expenses Weigh on Earnings 
US Judge Dismisses Gautam Adani Criminal Charges 
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 
Sony, TSMC Eye $6.3 Billion Japan Chip Venture for Next-Gen Image Sensors 
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss 
Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts 
Apple Tests China’s CXMT Memory Chips for iPhones and MacBooks Amid AI Supply Crunch 
Deutsche Bank Upgrades Persimmon to Buy After Strong First-Half Results 
Activist investor Starboard Value has fully exited its position in Pfizer, marking the end of a high-profile effort to pressure the pharmaceutical giant into boosting its flagging share price. According to a recent 13-F regulatory filing, Starboard sold approximately 8.5 million Pfizer shares during the third quarter, unwinding a stake that once totaled 15.4 million shares at the end of Q4 2024.
Starboard initially made waves when it disclosed a roughly $1 billion investment in Pfizer a year ago, stepping in at a time when the company’s stock was trading at roughly half its peak during the pandemic. The fund’s founder, Jeffrey Smith, was outspoken about Pfizer’s performance, arguing at an industry event that the board needed to hold management accountable for persistent underperformance and weak market confidence.
Despite its push for governance and operational improvements, Starboard’s campaign struggled to gain lasting traction. The firm had approached former Pfizer executives—including former CEO Ian Read—for strategic guidance, but discussions reportedly stalled. Pfizer’s current market value sits around $142 billion, a decline from roughly $162 billion when Starboard’s involvement was first revealed in October 2024.
Starboard, known for its aggressive activist strategies, has been active across several industries this year, taking positions in companies such as TripAdvisor, Rogers, and BILL Holdings, where it secured a board seat shortly after investing. However, its Pfizer exit marks a notable retreat from what was once one of its most closely watched campaigns.
The same filing also revealed that Starboard fully divested from Fortrea Holdings, a contract research organization spun off from LabCorp in 2023. The hedge fund sold 2.5 million Fortrea shares during the third quarter. Since Starboard disclosed its investment in October 2023, Fortrea’s share price has fallen nearly 50%, adding another setback to the fund’s recent positions.
Starboard declined to comment on the latest disclosures.
